GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SK Bioscience Co Ltd (XKRX:302440) » Definitions » Scaled Net Operating Assets

SK Bioscience Co (XKRX:302440) Scaled Net Operating Assets : 0.61 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is SK Bioscience Co Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

SK Bioscience Co's operating assets for the quarter that ended in Dec. 2024 was ₩1,685,488 Mil. SK Bioscience Co's operating liabilities for the quarter that ended in Dec. 2024 was ₩428,330 Mil. SK Bioscience Co's Total Assets for the quarter that ended in Sep. 2024 was ₩2,047,646 Mil. Therefore, SK Bioscience Co's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2024 was 0.61.


SK Bioscience Co Scaled Net Operating Assets Historical Data

The historical data trend for SK Bioscience Co's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SK Bioscience Co Scaled Net Operating Assets Chart

SK Bioscience Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Scaled Net Operating Assets
Get a 7-Day Free Trial 0.42 0.11 0.18 0.21 0.68

SK Bioscience Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 0.29 0.32 0.30 0.61

Competitive Comparison of SK Bioscience Co's Scaled Net Operating Assets

For the Biotechnology subindustry, SK Bioscience Co's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SK Bioscience Co's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SK Bioscience Co's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where SK Bioscience Co's Scaled Net Operating Assets falls into.


;
;

SK Bioscience Co Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

SK Bioscience Co's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2024 )
=(Operating Assets (A: Dec. 2024 )-Operating Liabilities (A: Dec. 2024 ))/Total Assets (A: Dec. 2023 )
=(1685487.879-428330.112)/1852439.18
=0.68

where

Operating Assets(A: Dec. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=2843596.037 - 1158108.158
=1685487.879

Operating Liabilities(A: Dec. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=821143.859 - 385857.239 - 6956.508
=428330.112

SK Bioscience Co's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2024 )
=(Operating Assets (Q: Dec. 2024 )-Operating Liabilities (Q: Dec. 2024 ))/Total Assets (Q: Sep. 2024 )
=(1685487.879-428330.112)/2047645.762
=0.61

where

Operating Assets(Q: Dec. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=2843596.037 - 1158108.158
=1685487.879

Operating Liabilities(Q: Dec. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=821143.859 - 385857.239 - 6956.508
=428330.112

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SK Bioscience Co Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of SK Bioscience Co's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


SK Bioscience Co Business Description

Traded in Other Exchanges
N/A
Address
310, Pangyo-ro, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13494
SK Bioscience Co Ltd is a South Korean pharmaceutical company. It is engaged in the manufacturing and developing of vaccine. The company has registered SKYCellflu prefilled syringe (PFS), the first cell culture influenza vaccine in Korea, followed by the licensure of SKYCellflu Quadrivalent prefilled syringe and 13-valent Pneumococcal Conjugate Vaccine. Further it has several other vaccines under development and clinical trials including recombinant rotavirus vaccine. In addition, the development of new typhoid conjugate vaccine and innovative pneumococcal vaccine is ongoing in collaboration with external partners.

SK Bioscience Co Headlines

No Headlines